Dr. David Healy, a formidable critic of the iron grip pharmaceutical corporations wield on the practice of psychiatry as well as on psychiatry’s deficient journal reports, directs his criticism at drug regulators in an article in the current British Medical Journal (BMJ).
Yesterday we forwarded an article about Tylenol-linked liver damage published by Associated Press. https://ahrp.org/cms/content/view/278/28/
Below two recent reports by Counterpunch.
Overreliance on toxic drugs is killing healthy people. And the FDA has done next to nothing to prevent drug-induced harm.
BBC reports: "TeGenero, a German pharmaceutical company, said it could not continue in business.Because of the fallout from the UK trial, it was impossible to attract investment, TeGenero said."
For almost two decades Eli Lilly has denied that evidence exists demonstrating that its antidepressant Prozac induced violence and suicidality.
Compare and contrast two recent news reports about TeenScreen: Lidia Wasowicz of United Press International provides readers with a sense of the controversy generated by psychiatry’s latest market expansion scheme.
The FDA appears to have learned nothing from recent catastrophic disasters.
Once again, the New England Journal of Medicine (July 13, 2006) has had to eat crow after it published false and misleading clinical trial findings.
Medical journals are supposed to be vehicles for scientific give and take–not so, evidently, in journals of the American Psychiatric Association.
A team of researchers from Columbia University and the University of Toronto, headed by Dr. Timothy Walsh (New York) tested the effect of antidepressants in the treatment of anorexia in a placebo controlled randomized trial.
A front page report in The New York Times describes a psychotropic drug-induced catastrophe that has befallen patients who obeyed their
psychiatrists, and swallowed the antipsychotic drugs prescribed by psychiatrists who insisted the drugs were for the patients own good.
One day following a rport in The New York Times, Sanifo-Aventis, manufacturer of Ketek, suspended the trial in children. The FDA has not announced any action.
